专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明授权

US11168265B2 Process of removing metal contaminants from light hydrocarbons 有权
公开(公告)号：US11168265B2
公开(公告)日：2021-11-09
申请号：US16741961
申请日：2020-01-14
申请人： Waynn Morgan , Jerry Weers , James Kiolbassa , Timothy O'Brien , Sai Reddy Pinappu , Tran minh Nguyen
发明人： Waynn Morgan , Jerry Weers , James Kiolbassa , Timothy O'Brien , Sai Reddy Pinappu , Tran minh Nguyen
IPC分类号： C10G19/02 , C10G21/06 , C10G29/06
摘要： A method of removing a metal contaminant from a light hydrocarbon stream comprises introducing a light hydrocarbon stream into a reactor vessel, the reactor vessel containing an aqueous treatment composition which comprises a treatment agent comprising one or more of the following: an alkali metal salt of a thiocarbonate; an alkaline earth metal salt of a thiocarbonate; an alkali metal salt of a tetrathioperoxy carbonate; or an alkaline earth metal salt of a tetrathioperoxy carbonate, the light hydrocarbon stream having an API gravity of greater than 28 degree determined in accordance with ASTM D 287-12 and comprising a metal contaminant; contacting the light hydrocarbon stream with the aqueous treatment composition generating a treated light hydrocarbon stream with a reduced level of the metal contaminant; and removing the treated light hydrocarbon stream from the reactor vessel.

52. 发明授权

US09556245B2 CA125 gene and its use for diagnostic and therapeutic interventions 有权
标题翻译： CA125基因及其在诊断和治疗干预中的应用
公开(公告)号：US09556245B2
公开(公告)日：2017-01-31
申请号：US12455366
申请日：2009-06-01
申请人： Timothy O'Brien , John Beard , Lowell Underwood
发明人： Timothy O'Brien , John Beard , Lowell Underwood
IPC分类号： C12Q1/68 , C07K14/47 , C07H21/00 , A61K38/00
CPC分类号： C07K14/47 , A61K38/00 , C12Q1/6886 , C12Q2600/156 , C12Q2600/158
摘要： The CA125 gene has been cloned and multiple repeat sequences as well as the carboxy terminus have been identified. The CA125 molecule comprises three major domains: an extracellular amino terminal domain (Domain 1); a large multiple repeat domain (Domain 2); and a carboxy terminal domain (Domain 3) which includes a transmembrane anchor with a short cytoplasmic domain. The amino terminal domain is dominated by its capacity for O-glycosylation and its resultant richness in serine and threonine residues. An amino terminal extension is presented, which comprises four genomic exons. The molecular structure is dominated by a repeat domain comprising 156 amino acid repeat units, which encompass the epitope binding sites. More than 60 repeat units have been identified, sequenced, and contiguously placed in the CA125 domain structure. More specifically, this invention is directed to a CA125 cDNA sequence which can be introduced into animal or human cells to achieve transcription or expression of the cDNA.
摘要翻译：已经克隆了CA125基因，并且已经鉴定了多个重复序列以及羧基末端。 CA125分子包含三个主要的结构域：细胞外氨基末端结构域（Domain 1）; 一个大的多重重复域（域2）; 和包含具有短细胞质结构域的跨膜锚的羧基末端结构域（结构域3）。氨基末端结构域以其O-糖基化的能力为主，其结果是丝氨酸和苏氨酸残基的丰富度。提供氨基末端延伸，其包含四个基因组外显子。分子结构由包含156个氨基酸重复单元的重复结构域所支配，其包含表位结合位点。已经确定，排序和连续地排列在CA125领域结构中的60多个重复单位。更具体地，本发明涉及可以引入动物或人类细胞以实现cDNA转录或表达的CA125 cDNA序列。

53. 发明申请

US20160335577A1 SYSTEMS AND METHODS FOR STATE MACHINE MANAGEMENT 审中-公开
标题翻译：国家机器管理系统与方法
公开(公告)号：US20160335577A1
公开(公告)日：2016-11-17
申请号：US15097842
申请日：2016-04-13
申请人： Kevin Richards , Arseny Bogomolov , Grigory Bonik , Victor Hsu , Alexander Visbal , John Carrino , Cooper Bills , Diran Li , William Rhyne , Timothy O'Brien , Matthew Bango
发明人： Kevin Richards , Arseny Bogomolov , Grigory Bonik , Victor Hsu , Alexander Visbal , John Carrino , Cooper Bills , Diran Li , William Rhyne , Timothy O'Brien , Matthew Bango
IPC分类号： G06Q10/06 , G06Q50/18 , G06F17/30
CPC分类号： G06Q10/06316 , G06F16/93 , G06Q10/06 , G06Q10/103 , G06Q50/18
摘要： A case management system is configured to provide one or more case generation and management functions. As configured, the case management system enables a user to define a workflow, the workflow including one or more states, one or more operations which may be performed at the one or more states, and one or more transitions corresponding to the operations and defining a sequence of the states; to generate and configure a state machine; to receive a workflow identifier to assign to the state machine; and through a command received from a client device, to open and manage a case based on the configuration of the state machine.
摘要翻译：案件管理系统被配置为提供一个或多个案例生成和管理功能。如配置的，病例管理系统使得用户能够定义工作流程，工作流程包括一个或多个状态，可以在一个或多个状态下执行的一个或多个操作以及对应于该操作的一个或多个转换并定义一个状态序列; 生成和配置状态机; 接收工作流标识符以分配给状态机; 并通过从客户端设备接收的命令，根据状态机的配置来打开和管理案例。

54. 发明授权

US08617883B2 Mesenchymal stem cell for promoting neovascularisation 有权
标题翻译：用于促进新生血管形成的间充质干细胞
公开(公告)号：US08617883B2
公开(公告)日：2013-12-31
申请号：US12183992
申请日：2008-07-31
申请人： Garry Paul Duffy , Frank Barry , Timothy O'Brien
发明人： Garry Paul Duffy , Frank Barry , Timothy O'Brien
IPC分类号： C12N5/08
CPC分类号： G01N33/5023 , A61K31/7088 , A61K35/12 , A61K38/19 , A61L15/44 , A61L17/005 , A61L27/3834 , A61L31/16 , A61L2300/64 , C12N5/0663 , C12N2501/998
摘要： The Eph (erythropoietin-producing hepatocellular carcinoma) receptors and their cell surface anchored ligands, the Ephrins, comprise the largest of the receptor tyrosine kinases families with 14 receptors and 8 ligands. The receptors are subdivided into Eph-A and Eph-B categories and have known actions in the development of the vascular and nervous system. The present invention relates to an isolated mesenchymal stem cell selected from the group consisting of an isolated mesenchymal stem cell that expresses Ephrin-B2, an isolated mesenchymal stem cell that over-expresses Ephrin-B2, and an isolated mesenchymal stem cell that is genetically modified to increase Ephrin-B2 expression. The invention further relates to the various applications of the isolated mesenchymal stem cells of the present invention.
摘要翻译： Eph（促红细胞生成素产生肝细胞癌）受体及其细胞表面锚定配体，Ephrins包含具有14个受体和8个配体的最大的受体酪氨酸激酶家族。受体被细分为Eph-A和Eph-B类别，并且在血管和神经系统的发育中具有已知的作用。本发明涉及分离的间充质干细胞，其选自表达Ephrin-B2的分离的间充质干细胞，过表达Ephrin-B2的分离的间充质干细胞和经遗传修饰的分离的间充质干细胞以增加Ephrin-B2表达。本发明还涉及本发明的分离的间充质干细胞的各种应用。

55. 外观设计

USD695932S1 Candle jar with bordered label 有权
公开(公告)号：USD695932S1
公开(公告)日：2013-12-17
申请号：US29391645
申请日：2011-05-11
申请人： Michael J. Kittredge, III , Michael J. Kittredge, II , John Hentz , Timothy O'Brien
设计人： Michael J. Kittredge, III , Michael J. Kittredge, II , John Hentz , Timothy O'Brien

56. 发明授权

US08323968B2 Osteopontin for the prediction and treatment of cardiovascular diseases 有权
标题翻译：骨桥蛋白预测和治疗心血管疾病
公开(公告)号：US08323968B2
公开(公告)日：2012-12-04
申请号：US12528610
申请日：2008-03-03
申请人： Timothy O'Brien , Frank Barry , Aaron Yie Loong Liew , Afshin Samali , Angela Duffy
发明人： Timothy O'Brien , Frank Barry , Aaron Yie Loong Liew , Afshin Samali , Angela Duffy
IPC分类号： C12N15/63 , C12N5/00 , C12N5/08 , C07K1/00
CPC分类号： A61K35/28 , A61K35/44
摘要： Osteopontin for the prediction and treatment of cardiovascular diseases The present invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for the treatment of cardiovascular diseases or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the risk of the development of these cardiovascular complications. In particular, the invention provides compositions and methods based on osteopontin and the genes encoding osteopontin.
摘要翻译：用于预测和治疗心血管疾病的骨桥蛋白本发明涉及内皮祖细胞（EPCs）和骨桥蛋白用于治疗心血管疾病或并发症的用途。本发明还涉及使用EPC骨桥蛋白水平作为发展这些心血管并发症风险的标志物。特别地，本发明提供了基于骨桥蛋白和编码骨桥蛋白的基因的组合物和方法。

57. 发明申请

US20100081941A1 CARDIOVASCULAR HEALTH STATION METHODS AND APPARATUS 审中-公开
标题翻译：心血管健康站方法和装置
公开(公告)号：US20100081941A1
公开(公告)日：2010-04-01
申请号：US11963681
申请日：2007-12-21
申请人： Morteza Naghavi , Robin Antony Owen , Albert Andrew Yen , Craig Jamieson , Haider Hassan , David Panthagani , Gary L. McQuilkin , Timothy O'Brien
发明人： Morteza Naghavi , Robin Antony Owen , Albert Andrew Yen , Craig Jamieson , Haider Hassan , David Panthagani , Gary L. McQuilkin , Timothy O'Brien
IPC分类号： A61B5/02
CPC分类号： A61B5/022 , A61B5/0066 , A61B5/015 , A61B5/02007 , A61B5/0261 , A61B5/0285 , A61B8/06
摘要： Methods and apparatus for improving measurements of cardiovascular health status in a given individual are provided. The comprehensive assessment of cardiovascular health includes at least two components: risk factor assessment based on epidemiologic studies and functional status of the individual. Structural studies of the individual can also be included in the comprehensive assessment of cardiovascular health. The invention aims to improve detection, treatment, devices, and administration of cardiovascular risk assessment.
摘要翻译：提供了用于改善给定个体心血管健康状况测量的方法和装置。心血管健康综合评估至少包括两个部分：基于流行病学研究的风险因素评估和个体功能状态。个人的结构研究也可以纳入心血管健康综合评估。本发明旨在改善心血管风险评估的检测，治疗，设备和管理。

58. 发明申请

US20090035819A1 CA125 gene and its use for diagnostic and therapeutic interventions 有权
公开(公告)号：US20090035819A1
公开(公告)日：2009-02-05
申请号：US11975668
申请日：2007-10-19
申请人： Timothy O'Brien , John Beard , Lowell Underwood
发明人： Timothy O'Brien , John Beard , Lowell Underwood
IPC分类号： C12P21/06 , C07H21/00 , C07K16/18 , C12N5/00
CPC分类号： C07K14/705 , C07K16/3092
摘要： The CA125 gene has been cloned and multiple repeat sequences as well as the carboxy terminus have been identified. The CA125 molecule comprises three major domains: an extracellular amino terminal domain (Domain 1); a large multiple repeat domain (Domain 2); and a carboxy terminal domain (Domain 3) which includes a transmembrane anchor with a short cytoplasmic domain. The amino terminal domain is assembled by combining five genomic exons, four very short amino terminal sequences and one extraordinarily large exon. This domain is dominated by its capacity for O-glycosylation and its resultant richness in serine and threonine residues. Additionally, an amino terminal extension is present, which comprises four genomic exons. The amino acid composition of the amino terminal extension was found to be consistent with the amino acid composition of the amino terminal domain. The molecular structure is dominated by a repeat domain comprising 156 amino acid repeat units, which encompass the epitope binding sites. More than 60 repeat units have been identified, sequenced, and contiguously placed in the CA125 domain structure. The repeat units encompass an interactive disulfide bridged C-enclosure and the site of OC125 and M11 binding. The repeat sequences demonstrated 70-85% homology to each other. Expression of the repeats was demonstrated in E. coli. The CA125 molecule is anchored at its carboxy terminal through a transmembrane domain and a short cytoplasmic tail. The carboxy terminal also contains a proteolytic cleavage site approximately 50 amino acids upstream from the transmembrane domain, which allows for proteolytic cleavage and release of the CA125 molecule. Any one of the repeat domains has the potential for use as a new gold standard for detecting and monitoring the presence of the CA125 antigen. Further, the repeat domains or other domains, especially the c-terminal to the repeat domain also provide a basis for the development of a vaccine, which would be useful for the treatment of ovarian cancer and other carcinomas where CA125 is elevated.

59. 发明申请

US20070118045A1 Iontophoresis challenge for monitoring cardiovascular status 审中-公开
标题翻译：用于监测心血管状态的离子电渗疗法挑战
公开(公告)号：US20070118045A1
公开(公告)日：2007-05-24
申请号：US11585781
申请日：2006-10-23
申请人： Morteza Naghavi , Timothy O'Brien , Craig Jamieson , Mark Johnson
发明人： Morteza Naghavi , Timothy O'Brien , Craig Jamieson , Mark Johnson
IPC分类号： A61B5/00 , A61B6/00 , A61B5/02
CPC分类号： A61B5/01 , A61B5/02007
摘要： Methods and apparatus are provided for determining individual vascular responses by employing iontophoresis to deliver vasoactive compounds to local area and determining resultant changes in blood flow by measuring changes in skin temperature as a correlate of local blood flow. The invention further provides methods and apparatus for assessing vascular reactivity in individuals under ambulatory conditions and relating stress responses to vascular reactivity.
摘要翻译：提供了用于通过使用离子电渗法将血管活性化合物递送至局部区域并通过测量皮肤温度变化作为局部血流量的相关性来确定血流变化的方法和装置。本发明进一步提供了用于评估在动态条件下个体的血管反应性并将应激反应与血管反应性相关联的方法和装置。

60. 发明申请

US20070015907A1 Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions 有权
公开(公告)号：US20070015907A1
公开(公告)日：2007-01-18
申请号：US10475117
申请日：2002-04-12
申请人： Timothy O'Brien , John Beard , Lowell Underwood
发明人： Timothy O'Brien , John Beard , Lowell Underwood
IPC分类号： C07K14/705 , C07H21/04
CPC分类号： C07K14/47 , A61K38/00 , C12Q1/6886 , C12Q2600/158
摘要： The CA125 gene has been cloned and multiple repeat sequences as well as the carboxy terminus have been identified. The CA125 molecule comprises three major domains: an extracellular amino terminal domain (Domain 1); a large multiple repeat domain (Domain 2); and a carboxy terminal domain (Domain 3) which includes a transmembrane anchor with a short cytoplasmic domain. The amino terminal domain is assembled by combining five genomic exons, four very short amino terminal sequences and one extraordinarily large exon. This domain is dominated by its capacity for O-glycosylation and its resultant richness in serine and threonine residues. Additionally, an amino terminal extension is present, which comprises four genomic exons. The amino acid composition of the amino terminal extension was found to be consistent with the amino acid composition of the amino terminal domain. The molecular structure is dominated by a repeat domain comprising 156 amino acid repeat units, which encompass the epitope binding sites. More than 60 repeat units have been identified, sequenced, and contiguously placed in the CA125 domain structure. The repeat units encompass an interactive disulfide bridged C-enclosure and the site of OC125 and M11 binding. The repeat sequences demonstrated 70-85% homology to each other. Expression of the repeats was demonstrated in E. coli. The CA125 molecule is anchored at its carboxy terminal through a transmembrane domain and a short cytoplasmic tail. The carboxy terminal also contains a proteolytic cleavage site approximately 50 amino acids upstream from the transmembrane domain, which allows for proteolytic cleavage and release of the CA125 molecule. Any one of the repeat domains has the potential for use as a new gold standard for detecting and monitoring the presence of the CA125 antigen. Further, the repeat domains or other domains, especially the c-terminal to the repeat domain also provide a basis for the development of a vaccine, which would be useful for the treatment of ovarian cancer and other carcinomas where CA125 is elevated.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式